Clinical trials: Adjuvant Radiotherapy
Pancreatic Cancer, Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Trial name
- NCT02723331
- Testing
- Nab paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Glioblastoma, Malignant Glioma
Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer
This study is for newly diagnosed WHO Grade IV malignant glioma patients to determine whether an investigational drug known as marizomib (MRZ) will improve the treatment of newly diagnosed glioblastoma patients by delaying the…
- Trial name
- NCT02903069
- Testing
- MRZ, TMZ, RT
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 66 people
- Sponsor
- Celgene
Lung Neoplasms
Concurrent Chemoradiotherapy Using Intensity Modulated Radiotherapy (IMRT) & Docetaxel-cisplatin (or Carboplatin) Followed by Adjuvant Chemotherapy for Inoperable Stage III Non-small-cell Lung Cancer
Primary Objective: Response rate (by contrast CT scan) Secondary Objectives: Progression-free survival (PFS) Overall survival (OS)
- Trial name
- C-CRISP (NCT01266512)
- Testing
- DOCETAXEL, Intensity Modulated Radiotherapy (IMRT), CISPLATIN
- Where
- Hong Kong
- Volunteers
- 34 people
- Sponsor
- Sanofi
Primary Glioblastoma, Glioblastoma Multiforme
LAM561 With RT and TMZ for Adults With Glioblastoma
The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with…
- Trial name
- CLINGLIO (NCT04250922)
- Testing
- LAM561, TMZ, RT
- Where
- 22 sites in France, Israel and 3 more
- Volunteers
- 144 people
- Sponsor
- Laminar Pharmaceuticals
Cutaneous Squamous Cell Carcinoma
Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
The primary objective of the study is to compare disease-free survival (DFS) of patients with high-risk cutaneous squamous cell carcinoma (CSCC) treated with adjuvant cemiplimab, versus those treated with placebo, after surgery…
- Trial name
- NCT03969004
- Testing
- Cemiplimab
- Where
- 166 sites in United States, Australia and 14 more
- Volunteers
- 415 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer (Adenocarcinoma), Prostate CA
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer.
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate CA, Prostate Cancers, Prostate Cancer (Post Prostatectomy)
- Trial name
- NCT06636682
- Testing
- FK-PC101, Standard of Care (SOC)
- Where
- 3 sites in United States
- Volunteers
- 100 people
- Sponsor
- Cellvax Therapeutics Inc
Postoperative or Postradiation Adjuvant Androgen Deprivation Therapy in Locally Advanced Prostate Cancer (High and Very High Risk) Patients
Non-Interventional Study PREVENT
This is a multicentre, non-interventional, prospective study to be carried out in representative medical institutions in order to get the information on administration of postoperative and post-radiation adjuvant androgen…
- Trial name
- PREVENT (NCT02155998)
- Where
- 14 sites in Russia
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Adults With Glioblastoma Multiforma
Nimotuzumab in Adults With Glioblastoma Multiforma
Determination of efficiency of nimotuzumab in adults with glioblastoma multiforma
- Trial name
- NCT00753246
- Testing
- nimotuzumab
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Oncoscience AG
Head and Neck Neoplasms
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
This randomised, double-blind phase III trial will be performed in patients with head and neck squamous cell carcinoma (HNSCC). The objectives of the trial are to compare the efficacy and safety of afatinib (BIBW 2992) with…
- Trial name
- NCT01345669
- Testing
- Afatinib
- Where
- 162 sites in United States, Argentina and 27 more
- Volunteers
- 617 people
- Sponsor
- Boehringer Ingelheim
Pleural Neoplasms
Phase II Trial of Neo-Adjuvant Pemetrexed Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma
This study aims to determine how successful the chemotherapy regimen of Pemetrexed plus cisplatin before surgery is at killing all the tumor so that none is left at the time of surgery.
- Trial name
- NCT00087698
- Testing
- pemetrexed, cisplatin
- Where
- 7 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eli Lilly and Company
Head and Neck Neoplasms
LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
This randomised, double-blind phase III trial will be performed in patients with head and neck squamous cell carcinoma (HNSCC). The objectives of the trial are to compare the efficacy and safety of afatinib (BIBW 2992) with…
- Trial name
- NCT02131155
- Testing
- Afatinib
- Where
- 17 sites in China, Singapore and 2 more
- Volunteers
- 36 people
- Sponsor
- Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
The reason for this study is to see if the study drug, selpercatinib, compared to placebo is effective and safe in delaying cancer return in participants with early-stage non-small cell lung cancer (NSCLC), who have already had…
- Trial name
- LIBRETTO-432 (NCT04819100)
- Testing
- Selpercatinib
- Where
- 211 sites in United States, Australia and 30 more
- Volunteers
- 152 people
- Sponsor
- Eli Lilly and Company
Glioblastoma, Small Cell Glioblastoma
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
This 2-arm, randomized, phase III study will investigate the efficacy and safety of the addition of rindopepimut (an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have tumors that express…
- Conditions
- Glioblastoma, Small Cell Glioblastoma, Giant Cell Glioblastoma, Gliosarcoma
- Trial name
- ACT IV (NCT01480479)
- Testing
- Rindopepimut (CDX-110) with GM-CSF, Temozolomide, KLH
- Where
- 223 sites in United States, Australia and 22 more
- Volunteers
- 745 people
- Sponsor
- Celldex Therapeutics
Head and Neck Neoplasms
Porfiromycin Used as an Adjuvant to Radiation Therapy in Postoperative Head and Neck Cancer Patients
Determination of efficacy and safety of porfiromycin versus placebo as an adjuvant to radiotherapy in postoperative head and neck a cancer patients as well as assessment of population pharmacokinetic parameters.
- Trial name
- NCT02183246
- Testing
- Porfiromycin, Radiotherapy
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
The purpose of this study is to evaluate the efficacy of TAK-385 for achieving and maintaining testosterone suppression.
- Trial name
- NCT02135445
- Testing
- TAK-385, Degarelix
- Where
- 25 sites in United States, United Kingdom
- Volunteers
- 103 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Endometrial Cancer
A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2…
- Trial name
- NCT07022483
- Testing
- Trastuzumab Deruxtecan, Chemotherapy
- Where
- 86 sites in United States, Argentina and 13 more
- Volunteers
- 710 people
- Sponsor
- Daiichi Sankyo
Cancer of Cervix
Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix
The purpose of this study is to compare the effectiveness of two methods of treating cancer of the cervix. Half the patients will receive gemcitabine plus cisplatin while undergoing radiation therapy, followed by adjuvant…
- Trial name
- NCT00191100
- Testing
- Gemcitabine, Cisplatin, Brachytherapy
- Where
- 7 sites in Argentina, Bosnia and Herzegovina and 5 more
- Volunteers
- 515 people
- Sponsor
- Eli Lilly and Company
Glioblastoma Multiforme
AQ4N in Combination With Radiotherapy and Temozolomide in Subjects With Newly Diagnosed Glioblastoma Multiforme
Phase 1b of the study, will evaluate the safety and tolerability of AQ4N treatment at three different dose levels. Phase 2a of the study, will further evaluate the safety, tolerability, and in addition efficacy of AQ4N treatment…
- Trial name
- NCT00394628
- Testing
- AQ4N, Temozolomide, Radiotherapy
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Novacea
Glioblastoma
Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy
To compare surgical tumor removal and GammaTile therapy followed by adjuvant systemic therapy (bevacizumab or lomustine) to surgical tumor removal followed by adjuvant systemic therapy (bevacizumab or lomustine) without GammaTile…
- Trial name
- PATHWAyS (NCT05900908)
- Testing
- Gamma Tile-Surgically Targeted Radiation Therapy (STaRT), Stereotactic Radiation Therapy
- Sponsor
- GT Medical Technologies, Inc.
Head and Neck Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell…
- Trial name
- NCT05386550
- Testing
- Xevinapant, IMRT
- Where
- 206 sites in United States, Argentina and 24 more
- Volunteers
- 166 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.